Details for Patent: 10,695,345

Which drugs does patent 10,695,345 protect, and when does it expire?

Patent 10,695,345 protects CAPLYTA and is included in one NDA.

This patent has ten patent family members in ten countries.

Summary for Patent: 10,695,345

Title:	Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Abstract:	The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
Inventor(s):	Li; Peng (New Milford, NJ), Davis; Robert (San Diego, CA)
Assignee:	INTRA-CELLULAR THERAPIES, INC. (New York, NY)
Application Number:	16/557,083
Patent Claim Types: see list of patent claims	Use; Compound; Process; Dosage form;

Drugs Protected by US Patent 10,695,345

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-002	Apr 22, 2022		RX	Yes	No			Y			TREATMENT OF SCHIZOPHRENIA
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No			Y			TREATMENT OF SCHIZOPHRENIA
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019		RX	Yes	Yes			Y			TREATMENT OF SCHIZOPHRENIA

International Family Members for US Patent 10,695,345

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019331490
Brazil	112021003838
Canada	3108558